1. Introduction {#s0005}
===============

Dementia is an overall term for conditions characterized by a decline in memory, cognitive and other thinking skills that affect a person\'s abilities. The total number of people with dementia worldwide was estimated at 35.6 million in 2010, and is projected to be 65.7 million in 2030 and 115.4 million in 2050 ([@bb0455]). Among the several types of dementia, Alzheimer\'s disease (AD) is the most common. AD was first identified more than 100 years ago. However, its symptoms, causes and risk factors were only discovered in the last 30 years ([@bb0005]).

Several cytokines including interleukin 1 (IL-1), IL-6, tumor necrosis factor-α (TNF-α) and transforming growth factor-β (TGF-β) have been reported to be associated with AD ([@bb0460]). Interleukins (ILs) are important components of the immune system, and a deficiency in them may lead to autoimmune disease or immune deficiency. Several studies have suggested that IL-1 is related to the pathogenesis of AD. Griffin et al. reported that IL-1 immunoreactivity was increased in AD compared with non-AD subjects ([@bb0155]). Sheng et al. suggested that overexpression of IL-1 was associated with evolution of neuritic plaques from diffuse amyloid-β (Aβ) deposits in AD ([@bb0395]). In addition, IL-1 promotes the amyloid precursor protein (APP) cleavage pathway ([@bb0035]). Similarly, IL-6 has been reported to be involved in AD pathogenesis. Quintanilla et al. reported that IL-6 was associated with increased levels of hyperphosphorylated tau protein in neurons ([@bb0335]). Furthermore, Braida et al. suggested that IL-6 deficiency was associated with learning and memory skills in mice ([@bb0030]). These findings suggested ILs to be important factors in AD pathogenesis.

Several epidemiological studies have investigated the association between genetic polymorphisms of IL genes and the risk of AD, including − 889C \> T (rs1800587) in IL-1α, − 511C \> T (rs16944) in IL-1β, − 174C \> G (rs1800795) in IL-6 and − 1082G \> A (rs1800896) in IL-10 ([@bb0015], [@bb0025], [@bb0120], [@bb0160], [@bb0285], [@bb0295], [@bb0355], [@bb0205], [@bb0325], [@bb0060], [@bb0135], [@bb0150], [@bb0175], [@bb0270], [@bb0315], [@bb0320], [@bb0400], [@bb0055], [@bb0105], [@bb0130], [@bb0225], [@bb0245], [@bb0250], [@bb0255], [@bb0275], [@bb0375], [@bb0420], [@bb0010], [@bb0040], [@bb0110], [@bb0170], [@bb0230], [@bb0280], [@bb0300], [@bb0370], [@bb0470], [@bb0220], [@bb0260], [@bb0380], [@bb0440], [@bb0090], [@bb0340], [@bb0350], [@bb0475], [@bb0020], [@bb0445], [@bb0070], [@bb0100], [@bb0305], [@bb0125], [@bb0185], [@bb0210], [@bb0385], [@bb0435], [@bb0045], [@bb0075], [@bb0215], [@bb0360], [@bb0390], [@bb0085], [@bb0430], [@bb0180], [@bb0265], [@bb0310], [@bb0290], [@bb0345], [@bb0415], [@bb0140], [@bb0200], [@bb0405], [@bb0410]). However, these epidemiological studies have reported inconsistent results. In addition, several previous meta-analyses have assessed the associations between four polymorphisms of the IL genes and the risk of AD. However, several further papers regarding this relationship between IL gene polymorphisms and the risk of AD have been published recently. It is thus necessary to update the data regarding the association between IL gene polymorphisms and the risk of AD.

Therefore, we have re-evaluated and updated the associations between the polymorphisms of four IL genes and the risk of AD using published studies.

2. Materials and methods {#s0010}
========================

2.1. Search strategy {#s0015}
--------------------

Two clinical researchers independently searched and reviewed the literature. We conducted a meta-analysis of the published literature to analyze the associations between IL gene polymorphisms and Alzheimer\'s disease. The search sources were the PubMed, Science Direct, Scopus, and Google Scholar databases, the search was conducted up to July 2015, and the following search terms were used: "interleukin 1 or interleukin 6 or interleukin 10" and "variant or polymorphism or SNP" in combination with "Alzheimer\'s disease". The reference lists in the published articles were reviewed to identify any studies missing from the database search. The workflow of the literature search is shown in [Fig 1](#f0005){ref-type="fig"}.

2.2. Selection criteria {#s0020}
-----------------------

All articles reporting the genotype frequencies of the following IL gene single-nucleotide polymorphisms (SNPs) were included: − 889C \> T, − 511C \> T, − 174C \> G and − 1082G \> A. As the studies were heterogeneous in terms of the number of cases and controls, racial composition, and the polymorphisms analyzed, we used the following inclusion criteria: hospital-based or population-based case--control studies on the associations of IL gene polymorphisms with AD, genotype frequencies of each polymorphism provided for cases and controls, genotype distribution in the control group confirmed by Hardy--Weinberg equilibrium (HWE), and English-language articles only. If overlapping cases and controls between studies were identified, only the most-complete study was included in this meta-analysis.

2.3. Data extraction {#s0025}
--------------------

Data extraction was performed by two reviewers. The following data were extracted from each study: last name of the first author, publication year, study region, participants\' ethnicity, sample size, genotype distribution of the polymorphisms of four interleukin genes in both cases and controls, and *p*-values for the HWE of genotype distribution of controls (p value less than 0.05 of HWE was considered to indicate significance).

2.4. Statistical analysis {#s0030}
-------------------------

The chi-squared test was used to determine whether the distribution of genotypes in the control group was in agreement with HWE. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the associations between four IL gene polymorphisms (− 889C \> T, − 511C \> T, − 174C \> G and--1082G \> A) and AD risk under the heterozygous, homozygous, dominant, and recessive models with fixed-effects (Mantel--Haenszel method) and random-effects models (Mantel--Haenszel method). Statistical heterogeneity between studies was evaluated using the I^2^ statistic. A random-effects model was used to calculate the pooled OR and 95% CI when I^2^ values \> 50% were considered to indicate significant heterogeneity between studies. A fixed-effects model was used when I^2^ values \< 50% were considered to indicate low heterogeneity between studies. We also performed subgroup analyses by ethnicity (Caucasian and Asian). The risk of small study bias, such as publication bias, was measured using funnel plots and further evaluated with Egger\'s linear regression test. It was assumed that large-sized studies would plot close to the mean in the absence of publication bias, whereas small-sized studies would be spread smoothly on both sides of the mean. All meta-statistical analyses were performed using the RevMan ver. 5.1 software (Cochrane Collaboration, Copenhagen, Denmark) and confirmed using the Comprehensive Meta-Analysis trial version. Two-sided *p*-values \< 0.05 were considered to indicate significance.

3. Results {#s0035}
==========

3.1. Characteristics of the included studies {#s0040}
--------------------------------------------

A total of 529 papers published before July 2015 was identified in the search of the four databases. Of them, a total of 21,864 cases and 40,321 controls from 93 individual studies were included in our meta-analysis. A total of 8641 cases and 14,214 controls from 34 studies (42 subgroup studies) that reported on the association between the IL-1α gene polymorphism (− 889C \> T) and risk of AD were included in the meta-analysis. A total of 3194 cases and 4621 controls from 18 studies (19 subgroup studies) that reported on the association between the IL-1β gene polymorphism (− 511C \> T) and risk of AD were included in the meta-analysis. A total of 5755 cases and 12,456 controls from 24 studies (30 subgroup studies) of IL-6 gene polymorphism (− 174G \> C) were included in the meta-analysis. Seventeen IL-10 gene polymorphism (− 1082G \> A) studies (23 subgroup studies) involving 4274 cases and 9030 controls were included in the meta-analysis. Most of the studies were performed in Caucasian populations. However, several studies were conducted in Asian populations (nine subgroup studies in IL-1α, six subgroup studies in IL-1β, one subgroup study in IL-6, and one subgroup study in IL-10). The characteristics of the studies are summarized in [Table 1](#t0005){ref-type="table"}.

3.2. IL genes polymorphisms and risk of AD {#s0045}
------------------------------------------

Forty-two subgroup studies involving 8641 cases and 14,214 controls identified an association between the − 889C \> T polymorphism and risk of AD. The distributions of the genotypes in the control groups from all studies followed HWE. Our comprehensive meta-analysis indicated that the − 889C \> T polymorphism was significantly associated with an increased risk of AD by three genetic models. The ORs of the homozygote (CC vs. TT), dominant (TT/CT vs. CC) and recessive (TT vs. CC/CT) models were 1.32, 1.09 and 1.32, respectively (95% CI: 1.18--1.49, 1.03--1.16 and 1.18--1.45, respectively) using a fixed-effects model ([Fig. 2](#f0010){ref-type="fig"}). However, heterozygote models (CC vs. TC) were not associated with risk of AD (OR: 1.05, 95% CI: 0.98--1.12). We also assessed the association between the − 889C \> T polymorphism and risk of AD in Caucasian populations by excluding nine Asian studies ([@bb0205], [@bb0225], [@bb0420], [@bb0230], [@bb0300], [@bb0475], [@bb0445], [@bb0185], [@bb0405]). Data from the Caucasian studies showed that three genetic models (homozygote, dominant and recessive) were related to an increased risk of AD (OR: 1.30, 95% CI: 1.15--1.47; OR: 1.07, 95% CI: 1.00--1.15; OR: 1.30, 95% CI: 1.16--1.46, respectively). However, the heterozygote model was not related to risk of AD. Nineteen subgroup studies on the − 511C \> T polymorphism of IL-1β included 3194 cases and 4621 controls. Of these, the distribution of genotypes in the control groups of two studies, [@bb0255] and [@bb0285], deviated from HWE (*p* \< 0.05). Our meta-analysis with HWE revealed that the − 511C \> T polymorphism was not associated with risk of AD (homozygote: OR = 0.95, 95% CI = 0.81--1.12 by fixed-effects model; heterozygote: OR = 0.94, 95% CI = 0.84--1.06 by fixed-effects model; dominant: OR = 0.95, 95% CI = 0.86--1.06 by fixed-effects model; recessive: OR = 0.98, 95% CI = 0.75--1.28 by random-effects model). Therefore, our meta-analysis suggested that the − 889C \> T polymorphism was significantly associated with an increased risk of AD. However, the − 511C \> T polymorphism was not related to risk of AD.

Thirty subgroup studies on the − 174G \> C polymorphism included 5755 cases and 12,456 controls. Of them, five studies deviated from HWE (*p* \< 0.05) ([@bb0015], [@bb0110], [@bb0075], [@bb0410]). The tendency of our meta-analysis indicated that the − 174G \> C polymorphism was related to a decreased risk of AD. However, this polymorphism was statistically not associated with risk of AD (homozygote: OR = 0.85, 95% CI = 0.64--1.13; heterozygote: OR = 0.99, 95% CI = 0.85--1.15; dominant: OR = 0.95, 95% CI = 0.80--1.13; recessive: OR = 0.83, 95% CI = 0.67--1.03) by a random-effects model. Consequently, our results suggested that the − 174G \> C polymorphism was not associated with risk of AD.

Twenty-three subgroup studies involving 4274 cases and 9030 controls identified an association between the − 1082G \> A polymorphism and risk of AD. Two studies of the association between the − 1082G \> A polymorphism and AD risk were conducted in Asian populations. Among previous studies, the results of four studies departed from HWE (*p* \< 0.05) ([@bb0250], [@bb0255], [@bb0180]). Our meta-analysis results showed that the − 1082G \> A polymorphism of IL-10 was not related to risk of AD. The ORs of four genetic models (homozygote, heterozygote, dominant and recessive) were 1.04, 1.12, 1.10 and 0.97, respectively, using a random-effects model (95% CIs: 0.85--1.28, 0.94--1.33, 0.93--1.29 and 0.83--1.14, respectively). The results of the meta-analysis are summarized in [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}.

3.3. Publication bias {#s0050}
---------------------

Publication bias is shown graphically with a funnel plot ([Fig. 3](#f0015){ref-type="fig"}). We confirmed publication bias using Egger\'s linear regression test, as the funnel plot shapes did not indicate distinct symmetry in all of the genetic models. We did not find any evidence of publication bias in most of the genetic models.

3.4. Heterogeneity and sensitivity {#s0055}
----------------------------------

No significant heterogeneity was found among the studies of the − 889C \> T polymorphism. However, significant heterogeneity was found in the recessive model for the − 511C \> T polymorphism, all genetic models (homozygote, heterozygote, dominant and recessive) for the − 174C \> G polymorphism and all genetic models for the − 1082G \> A polymorphism. Therefore, we applied fixed-effects and random-effects models in the meta-analysis ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}). We also performed a sensitivity test to assess the stability and reliability of the results by sequentially deleting each subgroup study from the meta-analysis. The sensitivity test results indicated that none of the subgroup studies altered the pooled OR, suggesting that our meta-analysis was stable and reliable.

4. Discussion {#s0060}
=============

Our meta-analysis summarizes the evidence to date regarding the association between four polymorphisms (− 889C \> T, − 511C \> T, − 172G \> C and − 1082G \> A) and the risk of AD. The results indicate that − 889C \> T was significantly associated with an increased risk of AD. However, three polymorphisms (− 511C \> T, − 172G \> C and − 1082G \> A) were statistically not related to the risk of AD.

Over the past decades, many genetic studies and meta-analyses have been performed to investigate the relationship between IL gene polymorphisms and the risk of AD. The most recent meta-analyses of the association between the four IL gene polymorphisms (− 889C \> T, − 511C \> T, 174G \> C and − 1082G \> A) and the risk of AD were reported in 2012 and 2013 ([@bb0095], [@bb0115], [@bb0190], [@bb0330], [@bb0240], [@bb0465]). A previous meta-analysis of − 889C \> T polymorphism had included twenty-eight studies and a total 12,817 subjects ([@bb0240]). They results indicated that − 889C \> T polymorphism was significantly associated with increased risk of AD. Furthermore, Caucasian studies revealed that this polymorphism was associated with increased risk of AD. However, most of genetic models (dominant, recessive and T allele vs. C allele) showed that − 889C \> T polymorphism was not associated with risk of AD in Asian. Similarly, our results showed that − 889C \> T polymorphism was associated with increased risk of AD in overall and Caucasian subgroup studies. In − 511C \> T polymorphisms, Yuan et al. reported that − 511C \> T polymorphism was not associated with risk of AD. Furthermore, subgroup studies demonstrated that − 511C \> T polymorphism was not related with AD in Europe, non-Europe, Caucasian and non-Caucasian. In addition, many genetic models showed that heterogeneity ([@bb0465]). Similar to previous meta-analysis, our results indicated that − 511C \> T polymorphism was not associated with risk of AD in overall and Caucasian subgroup studies. In 2012, Bona et al. suggested that GG vs. AG/AA model of − 1082G \> A polymorphism was modestly associated with risk of AD (OR: 0.82, 95% CI: 0.65--1.02). In addition, results of meta-analysis showed that moderate degree of heterogeneity between studies ([@bb0115]). In contrast, our results suggested that − 1082G \> A polymorphism was statistically not associated with risk of AD. However, degree of heterogeneity was similar to previous meta-analysis. As mentioned above, meta-analysis results of three polymorphisms (− 889C \> T, − 511 C \> T and − 1082G \> A) were similar to previous meta-analysis. However, the results of the − 174G \> C polymorphism were different. In 2012, Dai et al. reported an association between the − 174G \> C polymorphism and the risk of AD in a meta-analysis including 3101 cases and 3860 controls. The overall analysis showed that the − 174G \> C polymorphism was significantly associated with a decreased risk of AD using a recessive model (OR: 0.70, 95% CI: 0.54--0.90). In addition, the heterozygote model revealed that the − 174G \> C polymorphism was strongly associated with a decreased risk of AD (OR: 0.83, 95% CI: 0.60--0.96) ([@bb0095]). Similarly, Qi et al.\'s meta-analysis (4280 cases and 8788 controls) suggested that the recessive model (CC vs. GC/GG) was significantly associated with a decreased risk of AD (OR: 0.65, 95% CI: 0.52--0.82) ([@bb0330]). However, our meta-analysis (5755 cases and 12,456 controls) shows that all genetic models (homozygote, CC vs. GG; heterozygote, GC vs. GG; dominant CC/GC vs. GG; recessive models, CC vs. GC/GG) were significantly not associated with the risk of AD. The conflicting results between Qi et al. and our meta-analysis may be due to the included studies. Our meta-analysis contains an additional eight studies ([@bb0350], [@bb0075], [@bb0390], [@bb0085], [@bb0290], [@bb0345], [@bb0140], [@bb0410]). In addition, we deleted four studies ([@bb0195], [@bb0065], [@bb0425], [@bb0145]). Three studies ([@bb0145], [@bb0065] and [@bb0195]) provided deficient genotype data. Also, the genotype data presented by [@bb0425] group may overlap with that of [@bb0075] (Rotterdam study). However, the Qi et al. meta-analysis included these four studies.

Three limitations of this meta-analysis should be mentioned. First, most of the cases and controls were Caucasians. Thus, the lack of studies involving Asian populations may limit the general application of our results. Second, the studies included in our meta-analysis were limited to published reports. Unpublished reports or those published in non-international journals could not be included in the analysis. These problems may have affected the stability of the meta-analysis data. Third, AD is a multifactorial disease. However, we did not consider gene--gene or gene--environmental interactions---such as age, smoking, alcohol status, and progression of AD---which may have influenced the associations between IL gene polymorphisms and AD risk. Nevertheless, this meta-analysis improves our understanding of the associations between four polymorphisms of IL genes and the risk of AD.

Many studies have reported the association between several gene polymorphisms and the risk of AD. Coon et al., suggested that ε2/ε4, ε3/ε4 and ε4/ε4 variant types of ApoE significantly increased the risk of AD (odds ratios: 3.49, 4.32 and 25.31, respectively) compared with ε3/ε3 ([@bb0080]). In addition, meta-analysis data suggested that ApoE e4/e4 type was significantly associated with the prevalence of AD. Interestingly, meta-analyses indicated that the highest estimates were in Northern Europe and the lowest estimates were in Asia (prevalence 14.1%, 95% CI: 12.2--16.0 in Northern Europe; prevalence: 7.70%, 95% CI: 5.84--9.55 in Asia) ([@bb0450]). In addition, it is known that mutations in the presenilin-1 (PSEN-1) and presenilin-2 (PSEN-2) genes are related to AD. Manotas-Rodriguez et al. reported that the PSEN-1 polymorphism (rs165932) was probably associated with the risk of AD in the European sub-group (fixed effect model. OR: 1.19, 95% CI: 1.02--1.37, *p*-value \< 0.05) ([@bb0365]). In addition, a meta-analysis by Chen et al. suggested that the rs8383 polymorphism of PSEN-2 was associated with an increased risk of AD (C vs. T, OR: 1.16, 95% CI: 1.00--1.33, *p*-value: 0.043; CC vs. TT, OR: 1.37, 95% CI: 1.02--1.84, *p*-value: 0.037) ([@bb0050]). Furthermore, genome-wide association studies have provided several polymorphisms of candidate genes and loci for AD ([@bb0235], [@bb0165]). However, the associations between several polymorphisms of candidate genes and the risk of AD are still unclear. To better understand the genetic risk factors for AD, large scale studies are needed to validate the associations and further investigations should consider the effects of environmental factors and genetic interactions.

5. Conclusions {#s0065}
==============

In summary, our updated meta-analysis of 93 studies showed that the results of − 889C \> T polymorphism was statistically associated with the risk of AD. In contrast, three other polymorphisms were not associated with the risk of AD. In addition, our results of three polymorphisms (− 889C \> T, − 511C \> T and 1082G \> A) were similar to those of previous meta-analyses. However, our results for the − 174G \> C polymorphism differed from those of previous meta-analyses. Consequently, our results suggested that the − 889C \> T polymorphism may be a potential risk factor in AD. However, the other three polymorphisms may not be a risk factor for AD.
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###### 

Description of this meta-analysis of the association of four polymorphisms of IL genes with risk of Alzheimer\'s disease.

  IL-1α (− 889C \> T) study (author/year)   Study region   Ethnicity   Criteria                 Sample size (case/control)   Genotype distribution (case/control)   HWE (*p*-value)   Reference           
  ----------------------------------------- -------------- ----------- ------------------------ ---------------------------- -------------------------------------- ----------------- ----------- ------- ------------
  [@bb0055]                                 Spain          Caucasian   NINCDS-ADRDA             111/89                       61/42                                  41/34             9/13        0.171   [@bb0055]
  [@bb0060]                                 Spain          Caucasian   NINCDS-ADRDA             298/306                      161/195                                119/104           18/7        0.108   [@bb0060]
  [@bb0075] (I)                             Bonn           Caucasian   NINCDS-ADRDA-CERAD       235/210                      123/111                                93/78             19/21       0.192   [@bb0075])
  [@bb0075] (II)                            Bristol        Caucasian   198/56                   87/24                        8629                                   25/3              0.125               
  [@bb0075] (III)                           Nottingham     Caucasian   83/96                    36/46                        38/38                                  9/12              0.353               
  [@bb0075] (IV)                            OPTIMA         Caucasian   233/237                  124/102                      80/110                                 29/25             0.56                
  [@bb0075] (V)                             Oviedo         Caucasian   187/109                  95/52                        77/50                                  15/7              0.269               
  [@bb0075] (VI)                            Rotterdam      Caucasian   391/5110                 185/2574                     162/2111                               44/425            0.789               
  [@bb0075] (VII)                           Santander      Caucasian   302/374                  162/220                      114/127                                26/27             0.15                
  [@bb0085]                                 France         Caucasian   NINCDS-ADRDA             129/190                      60/90                                  61/85             8/15        0.409   [@bb0085]
  Deniz-Naranzo et al. (2008)               Spain          Caucasian   NINCDS-ADRDA             282/312                      138/168                                118/121           26/23       0.85    [@bb0100]
  [@bb0120]                                 Germany        Caucasian   NINCDS-ADRDA             259/191                      141/126                                97/62             21/3        0.131   [@bb0120]
  [@bb0125]                                 Turkey         Caucasian   DSM-IV                   104/103                      60/45                                  41/52             3/6         0.07    [@bb0125]
  [@bb0135]                                 USA            Caucasian   NINCDS-ADRDA             142/119                      73/59                                  59/49             10/11       0.858   [@bb0135]
  [@bb0150]                                 UK/France      Caucasian   NINCDS-ADRDA-DSM-III-R   294/503                      134/221                                126/217           34/65       0.309   [@bb0150]
  [@bb0160]                                 Italy          Caucasian   NINCDS-ADRDA             318/335                      140/142                                125/163           53/30       0.08    [@bb0160]
  [@bb0170]                                 UK             Caucasian   CERAD                    68/503                       30/221                                 31/220            7/62        0.528   [@bb0170]
  [@bb0175]                                 Australian     Caucasian   NINCDS-ADRDA             221/351                      98/153                                 94/168            29/30       0.087   [@bb0175]
  [@bb0185]                                 China          Asian       NINCDS-ADRDA-DSM-III-R   344/224                      272/183                                61/37             11/4        0.198   [@bb0185]
  [@bb0205]                                 Korean         Asian       NINCDS-ADRDA             126/221                      106/184                                20/27             0/0         0.321   [@bb0205]
  [@bb0225]                                 Taiwan         Asian       NINCDS-ADRDA             125/93                       104/72                                 20/21             1/0         0.22    [@bb0225]
  [@bb0230]                                 China          Asian       NINCDS-ADRDA-DSM-IV      145/181                      103/128                                41/52             1/1         0.076   [@bb0230]
  [@bb0270]                                 Finland        Caucasian   NINCDS-ADRDA-CERAD       110/73                       42/33                                  39/29             29/11       0.281   [@bb0270]
  [@bb0275]                                 US/UK          Caucasian   CERAD                    232/167                      103/82                                 99/74             30/11       0.291   [@bb0275]
  [@bb0285]                                 USA            Caucasian   NINCDS-ADRDA-DSM-III-R   297/204                      139/102                                126/86            32/16       0.717   [@bb0285]
  [@bb0290]                                 Brazil         Caucasian   NINCDS-ADRDA             120/412                      64/209                                 45/168            11/35       0.88    [@bb0290]
  [@bb0295]                                 US/UK          Caucasian   CERAD                    232/167                      103/82                                 99/74             30/11       0.291   [@bb0295]
  Nishmura et al. (2004)                    Japan          Asian       NINCDS-ADRDA             172/163                      141/126                                31/37             0/0         0.102   [@bb0300]
  [@bb0315]                                 Finland        Caucasian   NINCDS-ADRDA             237/513                      123/248                                91/209            23/56       0.235   [@bb0315]
  [@bb0325]                                 Sweden         Caucasian   NINCDS-ADRDA             198/175                      89/93                                  89/65             20/17       0.264   [@bb0325]
  Rebeck et al. (2000)                      USA            Caucasian   CERAD                    247/187                      119/97                                 103/74            25/16       0.725   [@bb0355])
  [@bb0360]                                 Italy          Caucasian   NINCDS-ADRDA             19/20                        12/7                                   3/10              4/3         0.852   [@bb0360]
  [@bb0375]                                 Italy          Caucasian   NINCDS-ADRDA             353/482                      165/229                                153/219           35/34       0.057   [@bb0375]
  [@bb0380] I)                              Italy          Caucasian   NINCDS-ADRDA             225/143                      117/83                                 90/56             18/4        0.128   [@bb0380]
  [@bb0380] (II)                            USA            Caucasian   NINCDS-ADRDA             121/93                       52/40                                  59/42             10/11       0.996   
  Serretti (2009) (I)                       Greece         Caucasian   DSM-IV                   86/113                       45/66                                  34/39             7/8         0.504   [@bb0385]
  Serretti (2009) (II)                      Italy          Caucasian   NINCDS-ADRDA             24/17                        12/12                                  8/4               4/1         0.432   
  [@bb0405]                                 China          Asian       NINCDS-ADRDA             201/257                      153/217                                45/37             3/3         0.328   [@bb0405]
  [@bb0420]                                 China          Asian       NINCDS-ADRDA             234/170                      212/147                                21/22             1/1         0.858   [@bb0420]
  [@bb0430]                                 Brazil         Caucasian   NINCDS-ADRDA             199/241                      96/136                                 84/91             19/14       0.811   [@bb0430]
  [@bb0445]                                 Taiwan         Asian       NINCDS-ADRDA             219/209                      182/174                                37/33             0/2         0.756   [@bb0445]
  [@bb0475] (abstract)                      China          Asian       --                       520/505                      369/407                                134/92            17/6        0.756   [@bb0475]
                                                                                                                                                                                                          

  IL-1β (− 511C \> T) study (author/year)   Study region   Ethnicity   Criteria                 Sample size (case/control)   Genotype distribution (case/control)   HWE (*p*-value)   Reference           
  ----------------------------------------- -------------- ----------- ------------------------ ---------------------------- -------------------------------------- ----------------- ----------- ------- -----------
  Deniz-Naranzo et al. (2008)               Spain          Caucasian   NINCDS-ADRDA             282/312                      117/158                                127/129           38/25       0.852   [@bb0100]
  [@bb0160]                                 Italy          Caucasian   NINCDS-ADRDA             317/305                      141/126                                130/144           46/35       0.523   [@bb0160]
  [@bb0170]                                 UK             Caucasian   CERAD                    68/479                       34/211                                 24/220            10/48       0.395   [@bb0170]
  [@bb0175]                                 Australian     Caucasian   NINCDS-ADRDA             220/351                      106/154                                84/160            30/37       0.631   [@bb0175]
  [@bb0200]                                 Korea          Asian       NINCDS-ADRDA-DSM-IV      86/625                       27/207                                 46/320            13/98       0.161   [@bb0200]
  [@bb0210]                                 Poland         Caucasian   NINCDS-ADRDA             331/219                      152/118                                147/85            32/16       0.897   [@bb0210]
  [@bb0230]                                 China          Asian       NINCDS-ADRDA-DSM-IV      145/181                      34/44                                  69/84             42/53       0.35    [@bb0230]
  [@bb0255]                                 China          Asian       NINCDS-ADRDA             90/100                       26/22                                  26/33             38/45       0.002   [@bb0255]
  [@bb0270]                                 Finland        Caucasian   NINCDS-ADRDA-CERAD       92/52                        35/25                                  47/25             10/2        0.159   [@bb0270]
  [@bb0280]                                 UK             Caucasian   NINCDS-ADRDA             133/156                      65/82                                  59/59             9/15        0.365   [@bb0280]
  [@bb0285]                                 USA            Caucasian   NINCDS-DSM-III-R-ADRDA   335/203                      131/72                                 164/112           40/19       0.009   [@bb0285]
  Nishmura et al. (2004)                    Japan          Asian       NINCDS-ADRDA             172/163                      61/44                                  77/82             34/37       0.919   [@bb0300]
  [@bb0310]                                 Brazil         Caucasian   NINCDS-ADRDA             188/263                      38/48                                  107/132           43/83       0.722   [@bb0310]
  [@bb0350]                                 Italy          Caucasian   NINCDS-ADRDA             105/644                      52/283                                 46/287            7/74        0.923   [@bb0350]
  [@bb0360]                                 Italy          Caucasian   NINCDS-ADRDA             19/20                        5/3                                    14/12             0/5         0.343   [@bb0360]
  [@bb0380] (I)                             Italy          Caucasian   NINCDS-ADRDA             225/143                      103/54                                 97/70             25/19       0.62    [@bb0380]
  [@bb0380] (II)                            USA            Caucasian   NINCDS-ADRDA             121/93                       50/38                                  60/40             11/15       0.419   [@bb0440]
  [@bb0440]                                 Taiwan         Asian       NINCDS-ADRDA             46/103                       17/27                                  13/52             16/24       0.915   [@bb0445]
  [@bb0445]                                 Taiwan         Asian       NINCDS-ADRDA-DSM-IV      219/209                      74/56                                  107/105           38/48       0.928   [@bb0440]
                                                                                                                                                                                                          

  Il-6 (− 174g \> c) study (author/year)   Study region   Ethnicity   Criteria                 Sample size (case/control)   Genotype distribution (case/control)   HWE (*p*-value)   Reference              
  ---------------------------------------- -------------- ----------- ------------------------ ---------------------------- -------------------------------------- ----------------- ----------- ---------- -----------
  [@bb0010]                                Italy          Caucasian   NINCDS-ADRDA-DSM-IV      59/64                        17/32                                  34/27             8/5         0.833      [@bb0010]
  [@bb0015]                                Germany        Caucasian   NINCDS-ADRDA             102/351                      33/99                                  56/208            13/44       \< 0.001   [@bb0015]
  [@bb0025]                                USA            Caucasian   NINCDS-ADRDA             464/337                      178/126                                221/155           65/56       0.478      [@bb0025]
  [@bb0040]                                Italy          Caucasian   NINCDS-ADRDA             168/220                      90/129                                 71/82             7/9         0.364      [@bb0040]
  [@bb0045]                                Italy          Caucasian   NINCDS-ADRDA             149/298                      81/172                                 61/111            7/15        0.590      [@bb0045]
  [@bb0075] (i)                            Bonn           Caucasian   NINCDS-ADRDA-CERAD       241/224                      81/77                                  123/95            37/52       0.035      [@bb0075]
  [@bb0075] (ii)                           Bristol        Caucasian   189/54                   66/9                         83/29                                  40/16             0.497                  
  [@bb0075] (iii)                          Nottingham     Caucasian   84/95                    33/32                        36/41                                  15/22             0.215                  
  [@bb0075] (iv)                           OPTIMA         Caucasian   243/240                  88/65                        106/141                                49/34             0.002                  
  [@bb0075] (v)                            Oviedo         Caucasian   190/119                  89/60                        82/51                                  19/8              0.517                  
  [@bb0075] (vi)                           Rotterdam      Caucasian   391/5110                 127/1824                     191/2426                               73/860            0.270                  
  [@bb0075] (vii)                          Santander      Caucasian   333/381                  148/169                      137/163                                48/49             0.328                  
  [@bb0085]                                France         Caucasian   NINCDS-ADRDA             231/470                      96/171                                 100/229           35/70       0.639      [@bb0085]
  [@bb0110]                                Germany        Caucasian   NINCDS-ADRDA             113/108                      33/26                                  65/64             15/18       0.046      [@bb0110]
  [@bb0130]                                Germany        Caucasian   NINCDS-ADRDA             101/133                      44/43                                  47/70             10/20       0.326      [@bb0130]
  [@bb0140]                                Italy          Caucasian   NINCDS-ADRDA             533/713                      216/160                                241/337           76/216      0.192      [@bb0140]
  [@bb0215]                                Poland         Caucasian   NINCDS-ADRDA             361/200                      119/66                                 185/91            57/43       0.271      [@bb0215]
  [@bb0220]                                Finland        Caucasian   --                       65/542                       18/136                                 32/260            15/146      0.349      [@bb0220]
  [@bb0245]                                Italy          Caucasian   NINCDS-ADRDA-DSM-IV-R    332/393                      137/209                                161/165           34/19       0.057      [@bb0245]
  [@bb0265]                                India          Caucasian   NINCDS-ADRDA             80/120                       55/88                                  24/29             1/3         0.743      [@bb0265]
  [@bb0290]                                Brazil         Caucasian   NINCDS-ADRDA-DSM-IV      120/412                      71/260                                 38/136            11/16       0.732      [@bb0290]
  [@bb0305]                                Poland         Caucasian   NINCDS-ADRDA             51/36                        11/12                                  31/16             9/8         0.549      [@bb0305]
  [@bb0320]                                Italy          Caucasian   NINCDS-ADRDA             124/134                      56/29                                  51/58             17/47       0.170      [@bb0320]
  [@bb0345]                                Brazil         Caucasian   NINCDS-ADRDA-DSM-IV      197/163                      88/82                                  91/65             18/16       0.557      [@bb0345]
  [@bb0350]                                Italy          Caucasian   NINCDS-ADRDA             105/644                      50/251                                 43/304            12/89       0.842      [@bb0350]
  Shawkatová et al. (2010)                 Slovakia       Caucasian   NINCDS-ADRDA             50/140                       23/53                                  21/66             6/21        0.951      [@bb0390]
  [@bb0400]                                Japan          Asian       NINCDS-ADRDA             128/83                       4/7                                    74/23             50/53       0.068      [@bb0400]
  [@bb0410]                                Mexico         Caucasian   NINCDS-ADRDA             94/100                       5/3                                    23/15             66/82       0.040      [@bb0410]
  [@bb0435]                                Turkey         Caucasian   NINCDS-ADRDA             101/138                      54/76                                  43/51             4/11        0.556      [@bb0435]
  [@bb0470]                                UK             Caucasian   NINCDS-ADRDA-DSM-III-R   356/434                      132/152                                171/213           53/69       0.695      [@bb0470]
                                                                                                                                                                                                            

  IL-10 (− 1082G \> A) study (author/year)   Study region   Ethnicity   Criteria              Sample size (case/control)   Genotype distribution (case/control)   HWE (*p*-value)   Reference              
  ------------------------------------------ -------------- ----------- --------------------- ---------------------------- -------------------------------------- ----------------- ----------- ---------- -----------
  [@bb0010]                                  Italy          Caucasian   NINCDS-ADRDA-DSM-IV   63/63                        4/14                                   28/29             31/20       0.573      [@bb0010]
  [@bb0020]                                  Italy          Caucasian   DSM-IV                222/179                      98/79                                  99/74             25/26       0.210      [@bb0020]
  [@bb0070]                                  Spain          Caucasian   NINCDS-ADRDA          231/194                      60/66                                  140/99            31/29       0.410      [@bb0070]
  [@bb0085]                                  France         Caucasian   NINCDS-ADRDA          426/475                      94/107                                 205/232           127/136     0.671      [@bb0085]
  [@bb0090]                                  Sweden         Caucasian   --                    160/92                       41/24                                  79/50             40/18       0.380      [@bb0090]
  [@bb0105]                                  Germany        Caucasian   NINCDS-ADRDA          233/97                       56/25                                  96/54             81/18       0.240      [@bb0105]
  [@bb0180] (I)                              Bonn           Caucasian   NINCDS-ADRDA-CERAD    245/216                      54/45                                  118/109           73/62       0.819      [@bb0180]
  [@bb0180] (II)                             Bristol        Caucasian   162/52                45/12                        72/25                                  45/15             0.799                  
  [@bb0180] (III)                            Nottingham     Caucasian   67/76                 21/22                        28/29                                  18/25             0.040                  
  [@bb0180] (IV)                             OPTIMA         Caucasian   237/241               72/58                        112/123                                53/60             0.747                  
  [@bb0180] (V)                              Oviedo         Caucasian   186/110               24/25                        97/61                                  65/24             0.252                  
  [@bb0180] (VI)                             Rotterdam      Caucasian   391/5110              120/1339                     190/2538                               81/1233           0.656                  
  [@bb0180] (VII)                            Santander      Caucasian   311/387               38/66                        182/185                                91/136            0.820                  
  [@bb0250]                                  Italy          Caucasian   NINCDS-ADRDA          132/213                      32/86                                  91/118            9/9         \< 0.001   [@bb0250]
  [@bb0260]                                  China          Asian       NINCDS-ADRDA          95/117                       3/5                                    8/6               84/106      \< 0.001   [@bb0260]
  [@bb0290]                                  Brazil         Caucasian   NINCDS-ADRDA          120/412                      15/35                                  68/189            37/188      0.192      [@bb0290]
  [@bb0340]                                  USA            Caucasian   NINCDS-ADRDA          265/347                      65/100                                 144/156           56/91       0.062      [@bb0340]
  [@bb0360]                                  Italy          Caucasian   NINCDS-ADRDA          19/20                        8/1                                    5/12              6/7         0.154      [@bb0360]
  [@bb0370]                                  Italy          Caucasian   NINCDS-ADRDA          215/153                      35/26                                  109/64            71/63       0.168      [@bb0370]
  [@bb0390]                                  Slovakia       Caucasian   NINCDS-ADRDA          50/140                       8/30                                   20/61             22/49       0.184      [@bb0390]
  [@bb0410]                                  Mexico         Caucasian   NINCDS-ADRDA          94/100                       8/9                                    86/91             0/0         \< 0.001   [@bb0410]
  [@bb0415]                                  Brazil         Caucasian   NINCDS-ADRDA-CERAD    249/98                       25/12                                  103/40            121/46      0.476      [@bb0415]
  [@bb0435]                                  Turkey         Caucasian   NINCDS-ADRDA          101/138                      24/50                                  65/63             12/25       0.511      [@bb0435]

Bonn, Ethics Review Board of the University of Bonn; Bristol, Frenchay Local Research Ethics committee Bristol; Nottingham, Nottingham Research Committee 2 (NHS); OPTIMA, Central Oxford Ethics Committee No 1656; Oviedo, Ethical Committee of the Hospital Central de Asturias; Rotterdam, Medical Ethical Committee of the Erasmus MC; Santander, Ethical Committee of the University Hospital "Marqués de Valdecilla", Santander; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer\'s disease and Related Disorders Association; CERAD, The Consortium to Establish a Registry for Alzheimer\'s Disease; DSM, Diagnostic and Statistical Manual of Mental Disorder. \*Zhou et al. data from abstract.

###### 

The associations between four polymorphisms of IL genes and AD risk.

                                    SNP                                                      Genetic models                 Pooled OR (95% CI)                                       Heterogeneity       Publication bias           
  --------------------------------- -------------------------------------------------------- ------------------------------ -------------------------------------------------------- ------------------- ------------------ ------- -------
  Overall                           rs1800587 (IL-1α; − 889C \> T)                           Homozygote model (TT vs. CC)   **1.32 (1.18--1.49)**[⁎](#tf0005){ref-type="table-fn"}   1.31 (1.13--1.51)   22%                0.110   0.900
  Heterozygote model (CT vs. CC)    1.05 (0.98--1.12)                                        1.04 (0.97--1.13)              24%                                                      0.080               0.174                      
  Dominant model (TT/CT vs. CC)     **1.09 (1.03--1.16)**[⁎](#tf0005){ref-type="table-fn"}   1.08 (1.00--1.17)              31%                                                      0.030               0.164                      
  Recessive model (TT vs. CC/CT)    **1.32 (1.18--1.45)**[⁎](#tf0005){ref-type="table-fn"}   1.30 (1.14--1.49)              18%                                                      0.160               0.897                      
  rs16944 (IL-1β; − 511C \> T)      Homozygote model (TT vs. CC)                             0.95 (0.82--1.11)              0.94 (0.77--1.16)                                        37%                 0.050              0.381   
  Heterozygote model (CT vs. CC)    0.93 (0.83--1.03)                                        0.92 (0.81--1.04)              24%                                                      0.160               0.323                      
  Dominant model (TT/CT vs. CC)     0.94 (0.85--1.04)                                        0.93 (0.82--1.05)              27%                                                      0.140               0.223                      
  Recessive model (TT vs. CC/CT)    0.97 (0.84--1.11)                                        0.98 (0.77--1.25)              61%                                                      \< 0.001            0.735                      
  rs1800795 (IL-6; − 174C \> G)     Homozygote model (GG vs. CC)                             0.79 (0.71--0.88)              0.83 (0.65--1.06)                                        74%                 \< 0.001           0.579   
  Heterozygote model (GG vs. GC)    0.95 (0.88--1.02)                                        0.96 (0.84--1.10)              62%                                                      \< 0.001            0.546                      
  Dominant model (CC/GC vs. GG)     0.92 (0.85--0.99)                                        0.92 (0.79--1.07)              72%                                                      \< 0.001            0.831                      
  Recessive model (CC vs. GG/GC)    0.80 (0.72--0.88)                                        0.83 (0.68--1.005)             68%                                                      \< 0.001            0.690                      
  rs1800896 (IL-10; − 1082G \> A)   Homozygote model (AA vs. GG)                             0.99 (0.88--1.13)              1.06 (0.87--1.29)                                        49%                 0.005              0.146   
  Heterozygote model (GA vs. GG)    1.11 (1.00--1.23)                                        1.16 (0.98--1.37)              50%                                                      0.004               0.517                      
  Dominant model (AA/GA vs. GG)     1.08 (0.97--1.19)                                        1.13 (0.96--1.33)              51%                                                      0.002               0.331                      
  Recessive model (AA vs. GG/GA)    0.93 (0.85--1.03)                                        0.97 (0.83--1.13)              49%                                                      0.005               0.177                      
  Caucasian                         rs1800587 (IL-1α; − 889C \> T)                           Homozygote model (TT vs. CC)   **1.30 (1.15--1.47)**[⁎](#tf0005){ref-type="table-fn"}   1.28 (1.10--1.50)   28%                0.070   0.796
  Heterozygote model (CT vs. CC)    1.03 (0.96--1.10)                                        1.03 (0.95--1.11)              12%                                                      0.280               0.435                      
  Dominant model (TT/CT vs. CC)     **1.07 (1.00--1.15)**[⁎](#tf0005){ref-type="table-fn"}   1.07 (0.99--1.16)              21%                                                      0.150               0.490                      
  Recessive model (TT vs. CC/CT)    **1.30 (1.16--1.46)**[⁎](#tf0005){ref-type="table-fn"}   1.28 (1.11--1.48)              26%                                                      0.090               0.780                      
  rs16944 (IL-1β; − 511C \> T)      Homozygote model (TT vs. CC)                             1.04 (0.87--1.26)              1.02 (0.77--1.35)                                        47%                 0.030              0.438   
  Heterozygote model (CT vs. CC)    0.96 (0.85--1.09)                                        0.96 (0.83--1.11)              25%                                                      0.190               0.378                      
  Dominant model (TT/CT vs. CC)     0.98 (0.88--1.11)                                        0.098 (0.85--1.13)             32%                                                      0.130               0.284                      
  Recessive model (TT vs. CC/CT)    1.02 (0.86--1.21)                                        1.01 (0.73--1.40)              66%                                                      \< 0.001            0.873                      
  rs1800795 (IL-6; − 174C \> G)     Homozygote model (GG vs. CC)                             0.78 (0.70--0.88)              0.82 (0.64--1.05)                                        75%                 \< 0.001           0.521   
  Heterozygote model (GG vs. GC)    0.94 (0.87--1.02)                                        0.94 (0.83--1.08)              60%                                                      \< 0.001            0.433                      
  Dominant model (CC/GC vs. GG)     0.91 (0.85--0.98)                                        0.91 (0.78--1.06)              73%                                                      \< 0.001            0.652                      
  Recessive model (CC vs. GG/GC)    0.82 (0.74--0.91)                                        0.86 (0.71--1.04)              66%                                                      \< 0.001            0.652                      
  rs1800896 (IL-10; − 1082G \> A)   Homozygote model (AA vs. GG)                             0.99 (0.87--1.13)              1.06 (0.87--1.29)                                        51%                 0.004              0.229   
  Heterozygote model (GA vs. GG)    1.11 (1.00--1.23)                                        1.15 (0.97--1.36)              52%                                                      0.003               0.628                      
  Dominant model (AA/GA vs. GG)     1.11 (1.00--1.23)                                        1.15 (0.97--1.36)              52%                                                      0.003               0.334                      
  Recessive model (AA vs. GG/GA)    0.93 (0.85--1.03)                                        0.97 (0.83--1.14)              52%                                                      0.003               0.172                      

Statistically significant (*p* \< 0.05).

###### 

Associations between four polymorphisms of IL genes and AD risk in studies in Hardy--Weinberg equilibrium (HWE).

  SNP                               Genetic models                                           Pooled OR (95% CI)                                       Heterogeneity       Publication bias   Departed from the HWE           
  --------------------------------- -------------------------------------------------------- -------------------------------------------------------- ------------------- ------------------ ----------------------- ------- -------------------------------------------------------------------
  rs1800587 (IL-1α; − 889C \> T)    Homozygote model (TT vs. CC)                             **1.32 (1.18--1.49)**[⁎](#tf0010){ref-type="table-fn"}   1.31 (1.13--1.51)   22%                0.110                   0.900   /
  Heterozygote model (CT vs. CC)    1.05 (0.98--1.12)                                        1.04 (0.97--1.13)                                        24%                 0.080              0.174                           
  Dominant model (TT/CT vs. CC)     **1.09 (1.03--1.16)**[⁎](#tf0010){ref-type="table-fn"}   1.08 (1.00--1.17)                                        31%                 0.030              0.164                           
  Recessive model (TT vs. CC/CT)    **1.32 (1.18--1.45)**[⁎](#tf0010){ref-type="table-fn"}   1.30 (1.14--1.49)                                        18%                 0.160              0.897                           
  rs16944 (IL-1β; − 511C \> T)      Homozygote model (TT vs. CC)                             0.95 (0.81--1.12)                                        0.94 (0.75--1.18)   42%                0.040                   0.284   [@bb0255] and [@bb0285]
  Heterozygote model (CT vs. CC)    0.94 (0.84--1.06)                                        0.94 (0.82--1.08)                                        29%                 0.130              0.924                           
  Dominant model (TT/CT vs. CC)     0.95 (0.86--1.06)                                        0.94 (0.82--1.08)                                        32%                 0.100              0.528                           
  Recessive model (TT vs. CC/CT)    0.96 (0.82--1.11)                                        0.98 (0.75--1.28)                                        63%                 \< 0.001           0.475                           
  rs1800795 (IL-6; − 174C \> G)     Homozygote model (GG vs. CC)                             0.79 (0.70--0.88)                                        0.85 (0.64--1.13)   78%                \< 0.001                0.670   [@bb0015], [@bb0075] (I), [@bb0075] (IV), [@bb0110] and [@bb0410]
  Heterozygote model (GG vs. GC)    0.97 (0.89--1.05)                                        0.99 (0.85--1.15)                                        64%                 \< 0.001           0.953                           
  Dominant model (CC/GC vs. GG)     0.93 (0.86--1.01)                                        0.95 (0.80--1.13)                                        76%                 \< 0.001           0.917                           
  Recessive model (CC vs. GG/GC)    0.79 (0.71--0.88)                                        0.83 (0.67--1.03)                                        70%                 \< 0.001           0.616                           
  rs1800896 (IL-10; − 1082G \> A)   Homozygote model (AA vs. GG)                             0.98 (0.86--1.12)                                        1.04 (0.85--1.28)   51%                0.005                   0.158   [@bb0180] (III), [@bb0250], [@bb0260] and [@bb0410]
  Heterozygote model (GA vs. GG)    1.07 (0.96--1.20)                                        1.12 (0.94--1.33)                                        51%                 0.006              0.631                           
  Dominant model (AA/GA vs. GG)     1.04 (0.94--1.16)                                        1.10 (0.93--1.29)                                        51%                 0.005              0.353                           
  Recessive model (AA vs. GG/GA)    0.93 (0.84--1.03)                                        0.97 (0.83--1.14)                                        55%                 0.002              0.144                           

[@bb0075] (I), Bonn, Ethics Review Board of the University of Bonn; [@bb0075] (IV), OPTIMA, Central Oxford Ethics Committee No 1656; [@bb0180], Nottingham, Nottingham Research Committee 2 (NHS).

− 889C \> T polymorphism of IL-1α studies were not departed from HWE.

Statistically significant (*p* \< 0.05).
